Acid-Activated Melittin for Targeted and Safe Antitumor Therapy

Area of Science:

• Biochemistry
• Pharmacology
• Biomaterials

Background:

• Melittin (MLT), a natural bee venom component, shows potential as an antitumor drug due to its ability to penetrate tumor cell membranes.
• However, its direct application is limited by potential toxicity and lack of tumor specificity.

Purpose of the Study:

• To develop a modified melittin (MLT-DMMA) with enhanced safety and targeted antitumor activity.
• To evaluate the biocompatibility and efficacy of MLT-DMMA in cancer treatment.

Main Methods:

• Chemical modification of MLT with 2,3-dimethyl maleimide (DMMA) to create a pH-sensitive amide bond.
• Characterization using MALDI-TOF MS, 1H NMR, IUPAC, and HPLC.
• In vitro assays for cell viability and hemolysis.
• In vivo animal experiments for safety evaluation.

Main Results:

• MLT-DMMA demonstrated decreased surface charge and lower cytotoxicity in physiological conditions compared to native MLT.
• Acid-activated cleavage of the amide bond was confirmed, enabling targeted drug release.
• The modified peptide exhibited timely antitumor activity specifically within acidic tumor microenvironments.

Conclusions:

• MLT-DMMA represents a feasible platform for improving targeted and safe antitumor drug delivery.
• The pH-sensitive modification enhances the therapeutic index of melittin for cancer treatment.